Individuals who had LVH and either cTnT or NTproBNP elevation were at a 4-fold higher risk of HF or CV death after multivariable adjustment for CV risk factors, renal function, and LV mass compared with those who did not have LVH and elevated biomarkers. This evidence concerns the gene TNNT2 and hydrops fetalis.